Patients with uncontrolled low-density lipoprotein cholesterol (LDL-C) who experience muscle pain on at least two statins achieved a greater LDL reduction with evolocumab (Repatha, Amgen) than with ezetimibe (Zetia, Merck), according to results of the GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3) study (JAMA 2016 Apr 3. [Epub ahead of print]).
GAUSS-3 was a two-phase study, which first randomized patients with uncontrolled LDL